Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three‐year follow‐up data of a single‐blind randomized controlled trial
Journal of the European Academy of Dermatology and Venereology · 2023
DOI: 10.1111/jdv.19089 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von Astrid M van Huizen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid, Psoriasis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Anti‐drug antibodies (ADA) are formed in patients treated with adalimumab (ADL). This might increase clearance of ADL, potentially causing a (secondary) non‐response. Combination therapy of ADL and methotrexate (MTX) reduces ADA levels and has a clinical benefit in rheumatologic diseases. In psoriasis however, the long‐term effectiveness and safety have not been studied.
Objectives
To investigate the three‐year follow‐up data of ADL combined with MTX compared to ADL monotherapy in ADL‐naive patients with moderate to severe plaque type psoriasis.
Methods
We conducted a multicentre RCT in the Netherlands and Belgium. Randomization was performed by a centralized online randomization service. Patients were seen every 12 weeks until week 145. Outcome assessors were blinded. We collected data on drug survival, effectiveness, safety, pharmacokinetics and immunogenicity of patients that started ADL combined with MTX compared to ADL monotherapy. We present descriptive analysis and patients were analysed according to the group initially randomized to. Patients becoming non‐adherent to the biologic were excluded from analyses.
Results
Sixty‐one patients were included and 37 patients (ADL group n = 17, ADL + MTX group n = 20) continued in the follow‐up study after 1 year. After 109 weeks and 145 weeks, there was a trend towards longer drug survival in the ADL + MTX group compared to the ADL group (week 109: 54.8% vs. 41.4%; p = 0.326, week 145: 51.6% vs. 41.4%; p = 0.464). At week 145, 7/13 patients were treated with MTX. In the ADL group, 4/12 patients that completed the study developed ADA, and 3/13 in the ADL + MTX group.
Conclusions
In this small study, there was no significant difference in ADL overall drug survival when it was initially combined with MTX, compared to ADL alone. Discontinuation due to adverse events was common in the combination group. To secure accessible healthcare, combination treatment of ADL and MTX can be considered in individual patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands.
- Department of Clinical Epidemiology and Data Science, Biostatistics and Bioinformatics, Amsterdam UMC, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
- National Heart Centre Singapore, Singapore City, Singapore.
- Radboud UMC, Radboud University, Department of Dermatology, Nijmegen, The Netherlands.
- Department of Dermatology, OLVG, Amsterdam, The Netherlands.
- Department of Dermatology, Erasmus MC, Rotterdam, The Netherlands.
ORCID-Profile: Astrid M van Huizen, Gayle E van der Kraaij, Celine I Busard, Wouter Ouwerkerk, Juul M P A van den Reek, Stef P Menting, Errol P Prens, Theo Rispens, Annick de Vries, Elke M G J de Jong, Jo Lambert, Martijn B A van Doorn, Phyllis I Spuls
Zitieren
APA
van Huizen, A. M., van der Kraaij, G. E., Busard, C. I., Ouwerkerk, W., van den Reek, J. M. P. A., Menting, S. P., Prens, E. P., Rispens, T., de Vries, A., de Jong, E. M. G. J., Lambert, J., van Doorn, M. B. A., & Spuls, P. I. (2023). Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three‐year follow‐up data of a single‐blind randomized controlled trial. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19089
Vancouver
van Huizen AM, van der Kraaij GE, Busard CI, Ouwerkerk W, van den Reek JMPA, Menting SP, et al. Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three‐year follow‐up data of a single‐blind randomized controlled trial. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.19089
BibTeX
@article{vanHuizen2023,
author = {van Huizen, Astrid M and van der Kraaij, Gayle E and Busard, Celine I and Ouwerkerk, Wouter and van den Reek, Juul M P A and Menting, Stef P and Prens, Errol P and Rispens, Theo and de Vries, Annick and de Jong, Elke M G J and Lambert, Jo and van Doorn, Martijn B A and Spuls, Phyllis I},
title = {Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three‐year follow‐up data of a single‐blind randomized controlled trial},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2023},
doi = {10.1111/jdv.19089}
}
EUVIMED